List of Excipients in Branded Drug ATAZANAVIR

Generic Drugs Containing ATAZANAVIR

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	atazanavir	31722-653	AMMONIA
Camber Pharmaceuticals Inc	atazanavir	31722-653	CROSPOVIDONE
Camber Pharmaceuticals Inc	atazanavir	31722-653	FD&C BLUE NO. 1
Camber Pharmaceuticals Inc	atazanavir	31722-653	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in ATAZANAVIR?

# Of NDCs	Excipient
6	ALCOHOL
7	AMMONIA
6	BUTYL ALCOHOL
2	CELLULOSE, MICROCRYSTALLINE

Atazanavir Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Atazanavir is an HIV-1 protease inhibitor with a formulation problem defined by poor, pH-dependent aqueous solubility. The strongest excipient opportunities are low-cost oral formulations that improve dissolution, reduce food and gastric-pH variability, support pediatric use, and enable competitive generic or differentiated products. The commercial opportunity is concentrated in atazanavir sulfate capsules, oral powder, fixed-dose combinations, and lower-cost formulations for markets where ritonavir- or cobicistat-boosted regimens remain clinically relevant.

What excipient properties are required for atazanavir?

Atazanavir is a weakly basic compound with substantially better solubility under acidic conditions. Gastric pH elevation caused by proton-pump inhibitors, H2-receptor antagonists, or other acid-reducing products can reduce exposure. The FDA label therefore contains specific restrictions on coadministration with acid-reducing agents and requires administration with food for some dosage forms (U.S. Food and Drug Administration [FDA], 2024a).

The excipient strategy should address four formulation objectives:

Objective	Formulation issue	Relevant excipient approach
Improve dissolution	Poor aqueous solubility and pH dependence	Acidifiers, surfactants, wetting agents, solid dispersions
Control dose variability	Dependence on gastric acidity and food	pH-modifying microenvironment, lipid-based delivery, improved dispersion
Support oral solid dosage	Powder flow, content uniformity, capsule filling	Lactose, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate
Expand patient access	Pediatric swallowing and taste limitations	Oral powder, taste masking, dispersible or multiparticulate systems

Atazanavir sulfate is the commercial active pharmaceutical ingredient used in REYATAZ. The salt form improves handling and provides a practical solid-state form, but it does not eliminate the need to manage dissolution and gastric-pH effects.

What excipients are used in REYATAZ capsules and oral powder?

REYATAZ capsules use conventional solid oral excipients. The FDA prescribing information identifies capsule excipients that include lactose monohydrate, crospovidone, magnesium stearate, gelatin, titanium dioxide, and colorants, with composition varying by strength and capsule shell (FDA, 2024a).

The oral powder formulation uses a different excipient platform because pediatric administration requires dispersion in food or liquid and improved palatability. The product contains sucrose and other formulation excipients, and the label includes administration instructions and warnings relating to aspartame exposure in applicable presentations (FDA, 2024a; DailyMed, 2024).

Current reference formulation architecture

Product type	Principal formulation function	Commercial implication
Hard gelatin capsule	Conventional powder blend containing atazanavir sulfate	Lowest development complexity for generic entry
Oral powder	Pediatric dosing and administration flexibility	Higher differentiation and more complex regulatory bridging
Acidified solid dosage form	Local pH reduction around drug particles	Potentially stronger dissolution and exposure profile
Lipid-based formulation	Solubilization and lymphatic or postprandial absorption support	Higher formulation and manufacturing complexity
Amorphous dispersion	Maintains drug in a higher-energy, rapidly dissolving state	Potential performance gain but greater physical-stability risk

The reference product’s conventional excipient system creates a relatively accessible entry point for generic capsule manufacturers. The primary barriers are bioequivalence, impurity control, powder handling, capsule content uniformity, and the need to reproduce dissolution across pH conditions.

Which excipient strategies can improve atazanavir bioavailability?

Acidifying excipients

Organic acids such as citric acid, fumaric acid, tartaric acid, or malic acid can create an acidic microenvironment near atazanavir particles. This approach may improve dissolution without requiring the entire dosage form or gastrointestinal tract to remain strongly acidic.

The commercial value depends on whether the formulation produces a reproducible improvement in dissolution and pharmacokinetic exposure. Key risks include:

• Acid-excipient incompatibility
• Moisture uptake
• Capsule-shell instability
• Variable acid distribution within the blend
• Local irritation
• Changes in impurity formation during accelerated storage

Acidifiers are attractive for immediate-release generic products because they are inexpensive and widely accepted in oral dosage forms. A formulation that uses a novel ratio, particle arrangement, coating, or manufacturing process may create patentable subject matter, although the excipient itself is unlikely to provide meaningful exclusivity.

Surfactants and wetting agents

Polysorbates, sodium lauryl sulfate, poloxamers, and related wetting agents may increase contact between atazanavir particles and gastrointestinal fluid. These excipients can reduce interfacial tension and improve dispersion.

The main development concern is dose-dependent tolerability and the possibility that a surfactant improves in vitro dissolution without producing a corresponding in vivo benefit. Surfactant levels should be minimized and evaluated against capsule-fill weight, impurity formation, and food-effect data.

Amorphous solid dispersions

Polyvinylpyrrolidone, copovidone, hydroxypropyl cellulose, and hypromellose acetate succinate can be evaluated as polymer carriers for amorphous atazanavir dispersions. The objective is to increase apparent solubility and delay recrystallization.

This strategy is more commercially defensible than a standard capsule blend but carries higher manufacturing risk. Critical parameters include:

• Drug loading
• Residual solvent
• Glass-transition temperature
• Moisture sensitivity
• Recrystallization during storage
• Milling and particle-size control

An amorphous dispersion could support a lower-dose product if exposure is improved, but any dose reduction would require clinical and regulatory substantiation. It should not be assumed that a superior dissolution profile will support a biowaiver for atazanavir.

Lipid-based systems

Medium-chain triglycerides, long-chain triglycerides, mono- and diglycerides, phospholipids, and self-emulsifying drug-delivery systems can improve apparent solubilization. Lipid systems may also reduce the difference between fasted and fed administration.

The main commercial opportunity is a differentiated product for patients with variable absorption or difficulty complying with food instructions. The principal disadvantages are capsule compatibility, oxidation, fill-volume requirements, manufacturing complexity, and a more demanding in vitro-in vivo correlation program.

Cyclodextrins and nanocrystals

Cyclodextrin complexes may improve aqueous dispersion, while nanocrystals increase surface area and dissolution rate. Both approaches can support liquid, pediatric, or dispersible products.

Their commercial value is strongest where the product must avoid large quantities of sugar, alcohol, or lipid excipients. The patentability opportunity may arise from particle-size distribution, stabilizer selection, process control, or a specific dosage form rather than from the use of a standard cyclodextrin or polymer.

What formulations are protected by atazanavir patents?

Atazanavir’s historical patent estate included composition-of-matter and pharmaceutical-composition protection associated with the active molecule and its salts. The core commercial product, REYATAZ, was approved by the FDA in 2003. The Orange Book has historically listed patents covering atazanavir-related products, but the principal U.S. exclusivity period has ended and atazanavir sulfate capsules are subject to generic competition (FDA, 2024b).

A practical formulation assessment is:

IP category	Relevance to a new atazanavir product	Current commercial significance
Atazanavir molecule	Broadest historical protection	Expired or no longer a primary U.S. entry barrier
Atazanavir sulfate or salt forms	May cover solid-state or salt-specific claims	Requires jurisdiction-by-jurisdiction review
Capsule composition	Can cover excipient ratios or release properties	Potential risk for technically differentiated generics
Oral powder	May cover pediatric dosage form and administration	More relevant to pediatric competitors
Method of use	May cover HIV treatment, boosting, or patient populations	Reduced blocking value where method claims have expired
Manufacturing process	Can cover crystallization, purification, or particle engineering	Relevant to API suppliers and vertical integration

Exact patent exposure depends on jurisdiction, claim scope, terminal disclaimers, patent-term adjustments, pediatric extensions, and whether a patent remains listed or enforceable. A U.S. product-specific freedom-to-operate review should use the current FDA Orange Book, issued patent records, and litigation docket rather than historical patent summaries.

When did atazanavir lose exclusivity?

Atazanavir’s principal U.S. small-molecule exclusivity has expired. FDA approval of REYATAZ occurred on June 20, 2003, and the product’s five-year new chemical entity exclusivity period ended in 2008. Pediatric exclusivity associated with later FDA activity extended certain regulatory protections, but it did not create a current barrier equivalent to active composition-of-matter protection.

Generic atazanavir sulfate capsules have entered the U.S. market. The commercial question is therefore no longer whether a conventional generic can enter after a future patent expiry. It is whether a manufacturer can obtain approval with acceptable bioequivalence, supply economics, and market access.

What is the Orange Book status of atazanavir?

The Orange Book identifies FDA-approved drug products, therapeutic-equivalence ratings, patent information, and exclusivity information. Atazanavir products should be reviewed by dosage form and strength because capsule and oral-powder presentations may have different regulatory records and patent listings (FDA, 2024b).

For business planning, the relevant status is:

• REYATAZ is an FDA-approved innovator product.
• Atazanavir sulfate capsules have generic competition.
• The key U.S. entry pathway is an abbreviated new drug application, not a biosimilar application.
• Paragraph IV certification remains relevant only to any unexpired listed patent that a proposed ANDA applicant seeks to challenge.
• A generic applicant must assess reference-listed-drug availability, dosage-form equivalence, bioequivalence, labeling, and supply-chain requirements.

Atazanavir is a small molecule. Biosimilar risk does not apply. The competitive risk comes from generic capsules, oral powders, fixed-dose antiretroviral regimens, and alternative protease-inhibitor products.

Which companies are challenging the atazanavir market?

Generic competition is likely to come from established antiretroviral suppliers and regional manufacturers with experience in regulated oral solids. The commercially relevant competitor groups are:

1. U.S. ANDA manufacturers supplying atazanavir sulfate capsules.
2. European and emerging-market suppliers serving public-health tenders.
3. Contract manufacturers offering low-cost API and finished-dose production.
4. Fixed-dose combination developers competing for the same HIV treatment budgets.
5. Manufacturers of alternative boosted protease inhibitors, particularly darunavir-based products.

Public tender economics can matter more than brand-level differentiation. Atazanavir is less commercially attractive than high-volume first-line antiretrovirals, so reliable API sourcing, low tablet or capsule cost, and stable regulatory documentation are central competitive factors.

What commercial opportunities exist for atazanavir excipients?

Low-cost generic capsules

The clearest opportunity is an immediate-release capsule using a robust powder blend. Excipients should prioritize:

• Rapid wetting
• Consistent flow
• Low lubricant sensitivity
• Stable capsule fill
• Reproducible dissolution in acidic and elevated-pH media
• Low cost per dose

A standard formulation can compete in public procurement if it reduces manufacturing cost without adding a complex clinical program.

Pediatric oral powder

Pediatric HIV treatment remains a differentiated formulation opportunity. An oral powder can improve dose flexibility and swallowing access, but the product must control taste, dose uniformity after reconstitution or dispersion, sugar content, microbial quality, and caregiver handling.

A sugar-reduced or sugar-free formulation could create a product position for children with dental, metabolic, or dietary concerns. The formulation would need strong palatability data because atazanavir’s bitter taste can undermine adherence.

Acidified multiparticulates

Multiparticulates containing acidified atazanavir sulfate could separate the drug from incompatible excipients, improve dispersion, and support dose flexibility. Taste-masked pellets or mini-tablets could be packaged in sachets or capsules.

This platform has greater IP potential than a conventional blend because claims may cover particle architecture, coating layers, acid distribution, and release behavior.

Fixed-dose combinations

Atazanavir has been used with ritonavir or cobicistat boosting. A fixed-dose or co-packaged regimen could reduce pill burden, but coformulation introduces compatibility and dose-ratio challenges. Ritonavir has its own solubility and excipient requirements, while cobicistat raises separate formulation and regulatory considerations.

The opportunity is commercially constrained by competition from established single-tablet HIV regimens and evolving treatment guidelines. A new atazanavir combination would need a clear advantage in cost, storage, dosing, or access.

What manufacturing and IP barriers affect atazanavir products?

The main manufacturing barriers are not raw excipient availability. They are process consistency and product performance. Important controls include API particle size, polymorphic form, moisture, blend segregation, acid distribution, lubricant concentration, capsule fill weight, and dissolution under multiple pH conditions.

Potentially protectable manufacturing elements include:

• A specific atazanavir sulfate particle-size range
• Controlled crystallization or milling
• Spray-dried or hot-melt-extruded dispersions
• Acidified multiparticulates
• Stabilized lipid preconcentrates
• Taste-masked pediatric particles
• A defined dissolution profile linked to improved exposure

A formulation patent is commercially useful only if the claims cover a product that competitors cannot easily design around. Broad claims to common excipients are vulnerable. Narrow claims tied to measurable performance, composition ranges, or manufacturing parameters are more defensible.

How does atazanavir compare with competing HIV protease inhibitors?

Product	Formulation profile	Commercial comparison
Atazanavir	pH-dependent solubility; capsule and powder products	Excipient-led differentiation remains possible, but generic pricing is strong
Darunavir	Oral tablets and suspension history; usually boosted	Larger modern commercial relevance in many treatment settings
Lopinavir/ritonavir	Historically complex liquid and tablet formulations	Significant formulation burden and strong legacy competition
Fosamprenavir	Prodrug-based oral formulation	Different solubility and dosing profile
Boosted atazanavir	Requires pharmacokinetic booster in many regimens	Coformulation and interaction management are key issues

Atazanavir can retain value where once-daily dosing, lower cost, and access-focused procurement outweigh the clinical preference for newer integrase-inhibitor regimens. Its excipient strategy should therefore support cost, stability, and administration rather than pursue high-cost technology without a clear clinical or regulatory benefit.

Key Takeaways

• Atazanavir’s central formulation challenge is poor, pH-dependent solubility.
• Acidifying excipients, wetting agents, amorphous dispersions, lipid systems, and nanocrystals are the principal technical options.
• Conventional capsule generics have the lowest development risk and the smallest differentiation opportunity.
• Pediatric oral powder and taste-masked multiparticulates offer stronger commercial differentiation.
• Atazanavir is a small molecule, so biosimilar competition does not apply.
• The primary U.S. exclusivity period has ended, and generic competition is established.
• Current business risk is driven by bioequivalence, API supply, generic pricing, public tenders, and competition from integrase-inhibitor regimens.
• The most defensible new IP is likely to involve particle engineering, microenvironmental pH control, multiparticulate architecture, or a defined manufacturing process.

FAQs

Can citric acid improve atazanavir dissolution?

Citric acid may improve local acidity and dissolution, but the benefit must be demonstrated through formulation-specific dissolution, stability, and pharmacokinetic studies.

Is atazanavir suitable for an amorphous solid dispersion?

It is a technically plausible candidate because of its poor solubility. Physical stability, recrystallization, moisture sensitivity, and manufacturing scalability are the main development risks.

Does atazanavir require a biosimilar pathway?

No. Atazanavir is a chemically synthesized small molecule. Generic competition proceeds through an ANDA or comparable national generic-drug pathway.

Is an atazanavir oral powder commercially attractive?

Yes, particularly for pediatric and access markets. The opportunity depends on taste masking, dose flexibility, storage stability, and evidence that caregivers can administer the product accurately.

What is the strongest patent opportunity in a new atazanavir formulation?

The strongest opportunity is usually a technically specific claim covering particle engineering, acidified microenvironment control, multiparticulates, taste masking, or a manufacturing process linked to measurable product performance.

References

1. DailyMed. (2024). REYATAZ- atazanavir sulfate capsule; REYATAZ- atazanavir sulfate powder. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2024a). REYATAZ (atazanavir sulfate) prescribing information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. National Library of Medicine. (2024). Atazanavir. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/compound/Atazanavir

5. World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. https://www.who.int/publications/-i/item/9789240031593